Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 2
Submit an article Journal homepage
1,338
Views
35
CrossRef citations to date
0
Altmetric
Drug Evaluation

Lasmiditan for the treatment of migraine

Matilde CapiExperimental Immunology Laboratory, Fondazione Luigi Maria Monti, IDI-IRCCS, Rome, ItalyView further author information
,
Fernando de AndrésCICAB Clinical Research Centre, Extremadura University Hospital and Medical School, Badajoz, Spain;Department of Analytical Chemistry and Food Technology, Faculty of Pharmacy, University of Castilla-La Mancha, Albacete, SpainORCID Iconhttp://orcid.org/0000-0003-1076-0743View further author information
ORCID Icon,
Luana LionettoAdvanced Molecular Diagnostic Unit, Fondazione Luigi Maria Monti, IDI-IRCCS, Rome, ItalyView further author information
,
Giovanna GentileNESMOS Department, Sapienza University of Rome, Rome, ItalyView further author information
,
Fabiola CipollaNESMOS Department, Sapienza University of Rome, Rome, ItalyView further author information
,
Andrea NegroDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy;Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, ItalyView further author information
,
Marina BorroNESMOS Department, Sapienza University of Rome, Rome, ItalyView further author information
,
Paolo MartellettiDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy;Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-6556-4128View further author information
ORCID Icon &
Martina CurtoDepartment of Clinical and Molecular Medicine, Sapienza University, Rome, Italy;Regional Referral Headache Centre, Sant’Andrea Hospital, Rome, Italy;Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy;Bipolar & Psychotic Disorders Program, McLean Hospital, Belmont, MA, USAView further author information
 show all
Pages 227-234 | Received 06 Sep 2016, Accepted 16 Dec 2016, Published online: 23 Jan 2017

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (9)

Daniele Martinelli, Vito Bitetto & Cristina Tassorelli. (2021) Lasmiditan: an additional therapeutic option for the acute treatment of migraine. Expert Review of Neurotherapeutics 21:5, pages 491-502.
Read now
Martina Curto, Fabiola Cipolla, Giusy Ylenia Cisale, Matilde Capi, Valerio Spuntarelli, Martina Guglielmetti, Paolo Martelletti & Luana Lionetto. (2020) Profiling lasmiditan as a treatment option for migraine. Expert Opinion on Pharmacotherapy 21:2, pages 147-153.
Read now
Andrea Negro & Paolo Martelletti. (2019) Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. Expert Review of Neurotherapeutics 19:8, pages 769-776.
Read now
Martina Curto, Matilde Capi, Paolo Martelletti & Luana Lionetto. (2019) How do you choose the appropriate migraine pharmacotherapy for an elderly person?. Expert Opinion on Pharmacotherapy 20:1, pages 1-3.
Read now
Jessica C Oswald & Nathaniel M Schuster. (2018) Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. Journal of Pain Research 11, pages 2221-2227.
Read now
Andrea Negro, Angela Koverech & Paolo Martelletti. (2018) Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. Journal of Pain Research 11, pages 515-526.
Read now
Abimael González-Hernández, Bruno A. Marichal-Cancino, Antoinette MaassenVanDenBrink & Carlos M. Villalón. (2018) Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opinion on Drug Metabolism & Toxicology 14:1, pages 25-41.
Read now
Bianca Raffaelli, Heike Israel, Lars Neeb & Uwe Reuter. (2017) The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opinion on Pharmacotherapy 18:13, pages 1409-1415.
Read now
Paolo Martelletti. (2017) Acute treatment of migraine: quo vadis?. Expert Opinion on Pharmacotherapy 18:11, pages 1035-1037.
Read now

Articles from other publishers (26)

Dimos D. Mitsikostas, Christian Waeber, Margarita Sanchez-del-Rio, Bianca Raffaelli, Håkan Ashina, Antoinette Maassen van den Brink, Anna Andreou, Patricia Pozo-Rosich, Alan Rapoport, Messoud Ashina & Michael A. Moskowitz. (2023) The 5-HT1F receptor as the target of ditans in migraine — from bench to bedside. Nature Reviews Neurology 19:8, pages 489-505.
Crossref
Reza Emadi, Abbas Bahrami Nekoo, Fatemeh Molaverdi, Zahra Khorsandi, Reza Sheibani & Hojjat Sadeghi-Aliabadi. (2023) Applications of palladium-catalyzed C–N cross-coupling reactions in pharmaceutical compounds. RSC Advances 13:27, pages 18715-18733.
Crossref
Varun Tiwari & Sachin Agrawal. (2022) Migraine and Neuromodulation: A Literature Review. Cureus.
Crossref
Paolo Martelletti. 2022. Migraine in Medicine. Migraine in Medicine 639 881 .
Paolo Martelletti. 2022. Migraine in Medicine. Migraine in Medicine 453 637 .
Ping Gu, Cheng Chen, Qian Wu, Changhong Dong, Teng Wang, Qi Wan & Xin Dong. (2021) The Effect and Safety of 5-HT1F Receptor Agonist Lasmiditan on Migraine: A Systematic Review and Meta-Analysis. BioMed Research International 2021, pages 1-14.
Crossref
Paul A DeJulio, Joshua K Perese, Nathaniel M Schuster & Jessica C Oswald. (2021) Lasmiditan for the acute treatment of migraine. Pain Management 11:5, pages 437-449.
Crossref
Max Tsai, Emel Serap Monkul Nery, Lisa Kerr, Rashna Khanna, Mika Komori, Ellen B. Dennehy, Darren Wilbraham & Paul Winner. (2021) Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine. Clinical Pharmacokinetics 60:6, pages 819-828.
Crossref
Matilde Capi, Valerio De Angelis, Donatella De Bernardini, Ottavia De Luca, Fabiola Cipolla, Luana Lionetto, Maurizio Simmaco & Paolo Martelletti. (2021) CGRP Receptor Antagonists and 5-HT1F Receptor Agonist in the Treatment of Migraine. Journal of Clinical Medicine 10:7, pages 1429.
Crossref
Anna Ferrari & Cecilia Rustichelli. (2021) Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review. Clinical Therapeutics 43:4, pages 654-670.
Crossref
Min Hou, Haiyan Xing, Chen Li, Xianfeng Wang, Dongmei Deng, Juan Li, Pan Zhang & Jianhong Chen. (2020) Short-term efficacy and safety of lasmiditan, a novel 5-HT1F receptor agonist, for the acute treatment of migraine: a systematic review and meta-analysis. The Journal of Headache and Pain 21:1.
Crossref
Richard B. Lipton, Louise Lombard, Dustin D. Ruff, John H. Krege, Li Shen Loo, Andrew Buchanan, Thomas E. Melby & Dawn C. Buse. (2020) Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study. The Journal of Headache and Pain 21:1.
Crossref
Stewart J. Tepper, Raghavendra Vasudeva, John H. Krege, Suchitrita S. Rathmann, Erin Doty, Bert B. Vargas, Delphine Magis & Mika Komori. (2020) Evaluation of 2‐Hour Post‐Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult‐to‐Treat Migraine Attacks. Headache: The Journal of Head and Face Pain 60:8, pages 1601-1615.
Crossref
Jill C Rau, Edita Navratilova, Janice Oyarzo, Kirk W Johnson, Sheena K Aurora, Todd J Schwedt, David W Dodick & Frank Porreca. (2020) Evaluation of LY573144 (lasmiditan) in a preclinical model of medication overuse headache. Cephalalgia 40:9, pages 903-912.
Crossref
Melissa J. Buskes & Maria-Jesus Blanco. (2020) Impact of Cross-Coupling Reactions in Drug Discovery and Development. Molecules 25:15, pages 3493.
Crossref
Max Tsai, Michael Case, Paul Ardayfio, Helen Hochstetler & Darren Wilbraham. (2020) Effects of Lasmiditan on Cardiovascular Parameters and Pharmacokinetics in Healthy Subjects Receiving Oral Doses of Propranolol. Clinical Pharmacology in Drug Development 9:5, pages 629-638.
Crossref
Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li Shen Loo, Mika Komori & Joshua Tobin. (2019) Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans. Cephalalgia 40:1, pages 19-27.
Crossref
Alan M. Rapoport & Peter McAllister. (2019) The Headache Pipeline: Excitement and Uncertainty. Headache: The Journal of Head and Face Pain 60:1, pages 190-199.
Crossref
László Vécsei, Melinda Lukács, János Tajti, Ferenc Fülöp, József Toldi & Lars Edvinsson. (2019) The Therapeutic Impact of New Migraine Discoveries. Current Medicinal Chemistry 26:34, pages 6261-6281.
Crossref
Messoud Ashina, Raghavendra Vasudeva, Leah Jin, Louise Lombard, Elizabeth Gray, Erin G. Doty, Laura Yunes‐Medina, Kraig S. Kinchen & Cristina Tassorelli. (2019) Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double‐Blind Placebo‐Controlled Phase 3 Clinical Studies. Headache: The Journal of Head and Face Pain 59:10, pages 1788-1801.
Crossref
Jan Lewis Brandes, Suzanne Klise, John H Krege, Michael Case, Rashna Khanna, Raghavendra Vasudeva, Joel Raskin, Eric M Pearlman & David Kudrow. (2019) Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study). Cephalalgia 39:11, pages 1343-1357.
Crossref
Richard Hargreaves & Jes Olesen. (2019) Calcitonin Gene‐Related Peptide Modulators – The History and Renaissance of a New Migraine Drug Class. Headache: The Journal of Head and Face Pain 59:6, pages 951-970.
Crossref
Shema Mathew & Jessica Ailani. (2019) Traditional and Novel Migraine Therapy in the Aging Population. Current Pain and Headache Reports 23:6.
Crossref
Daniel Martins. 2019. The Serotonin System. The Serotonin System 203 224 .
Marta Vila-Pueyo. (2018) Targeted 5-HT1F Therapies for Migraine. Neurotherapeutics 15:2, pages 291-303.
Crossref
N. Karsan, P. Prabhakar & P. J. Goadsby. (2017) Premonitory Symptoms of Migraine in Childhood and Adolescence. Current Pain and Headache Reports 21:7.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.